ALVO
Alvotech
$3.54
-5.35%
$1.2B
No data for this timeframe.
Vol
Market Cap$1.2B
Cap SizeSmall Cap
Analyst ConsensusStrong Buy (75%)
Reddit Sentiment71° Bullish
SEC Reports4
Press Releases4
Exchange Nasdaq·Sector Biological Products, (No Diagnostic Substances)·Inc. N4·CIK 0001898416·Prev Close $3.74
Recent Activity
Jun 4, 2026
Press
Alvotech resubmitted BLAs to the FDA for AVT05 (Simponi biosimilar) and AVT06 (Eylea biosimilar) after responding to a P
Impact 7/10
Jun 4, 2026
contract
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
<p>REYKJAVIK, Iceland, June 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a glob
May 11, 2026
Press
Alvotech announced that the FDA completed a routine cGMP surveillance inspection of its Reykjavik facility, issuing a Fo
Impact 4/10
May 11, 2026
SEC
Alvotech announced FDA completed a cGMP surveillance inspection of its manufacturing facility, issuing a Form 483 with o
PRESS-RELEASE — Impact 6/10
May 6, 2026
SEC
Alvotech reported Q1 2026 revenue of $105.9M, down 20.3% YoY from $132.8M, due to a production slowdown. Despite the dec
PRESS-RELEASE — Impact 6/10
May 6, 2026
SEC
Alvotech reported Q1 2026 revenue of $105.9M (down 20% YoY) and a GAAP EPS of -$0.37, far below the $0.06 consensus, due
PRESS-RELEASE — Impact 7/10
Price Targets
$13.83
+290.8% upside
Strong Buy
Current $3.54
Low $4.00
Median $7.50
High $50.00
6 analysts
$4.00
$50.00
Analyst Ratings
3Strong Buy
6Buy
2Hold
1Sell
0Strong Sell
Recent Analyst Actions
| Date | Firm | Action | Rating |
|---|---|---|---|
| Mar 24, 2026 | UBS | MAINTAIN | Buy → Buy |
| Mar 24, 2026 | Barclays | MAINTAIN | Underweight → Underweight |
| Dec 9, 2025 | Barclays | INITIATE | Underweight |
Earnings Estimates
| Period | EPS Est. | Range | Growth | # |
|---|---|---|---|---|
| Current Q | $-0.00 ▲ +98.3% | $-0.00 — $-0.00 | -103% YoY | 1 |
| Next Q | $0.01 ▲ +197.7% | $0.01 — $0.01 | 109% YoY | 1 |
| Current FY | $0.06 ▲ +1628.1% | $0.02 — $0.10 | 157% YoY | 2 |
| Next FY | $0.18 ▲ +0.6% | $-0.01 — $0.45 | 217% YoY | 4 |
Latest Reports
BULLISH
Press
7/10
Alvotech resubmitted BLAs to the FDA for AVT05 (Simponi biosimilar) and AVT06 (Eylea biosimilar) after responding to a P
Jun 4, 2026
BULLISH
PRESS-RELEASE
6/10
Alvotech announced FDA completed a cGMP surveillance inspection of its manufacturing facility, issuing a Form 483 with o
May 11, 2026
BEARISH
PRESS-RELEASE
6/10
Alvotech reported Q1 2026 revenue of $105.9M, down 20.3% YoY from $132.8M, due to a production slowdown. Despite the dec
May 6, 2026
Reddit Sentiment
71°
Bullish
Bearish
Neutral
Bullish
No institutional holding data available yet. Data is sourced from 13F filings which are filed quarterly.
No insider trading data available yet. Insider transactions are collected from SEC Form 4 filings.
4 SEC filing reports analyzed. Sentiment: 1 bullish, 2 bearish, 0 mixed, 1 neutral. Avg impact: 5.5/10.
BULLISH
PRESS-RELEASE
6/10
Alvotech announced FDA completed a cGMP surveillance inspection of its manufacturing facility, issui
May 11, 2026
BEARISH
PRESS-RELEASE
6/10
Alvotech reported Q1 2026 revenue of $105.9M, down 20.3% YoY from $132.8M, due to a production slowd
May 6, 2026
BEARISH
PRESS-RELEASE
7/10
Alvotech reported Q1 2026 revenue of $105.9M (down 20% YoY) and a GAAP EPS of -$0.37, far below the
May 6, 2026
NEUTRAL
PRESS-RELEASE
3/10
Alvotech announced it will release Q1 2026 financial results on May 6, 2026, with a webcast and Q&A
Apr 24, 2026
BULLISH
7/10
Alvotech resubmitted BLAs to the FDA for AVT05 (Simponi biosimilar) and AVT06 (Eylea biosimilar) aft
Jun 4, 2026
NEUTRAL
4/10
Alvotech announced that the FDA completed a routine cGMP surveillance inspection of its Reykjavik fa
May 11, 2026
NEUTRAL
2/10
Alvotech announced it will release its Q1 2026 financial results on May 6, 2026, followed by a webca
Apr 24, 2026
NEUTRAL
3/10
Alvotech announced it will release its Q4 and full-year 2025 financial and operating results on Marc
Mar 4, 2026
Current analyst consensus: Buy (75% buy). Based on 12 analysts: 3 strong buy, 6 buy, 2 hold, 1 sell, 0 strong sell.
Analyst Price Targets
$13.83 mean target
+290.8% upside
Strong Buy (2.00)
$4.00 Low
$50.00 High
| Metric | Value |
|---|---|
| Current Price | $3.54 |
| Target Low | $4.00 |
| Target Mean | $13.83 |
| Target Median | $7.50 |
| Target High | $50.00 |
| # Analysts | 6 |
| Recommendation | Strong Buy (2.00) |
Earnings Estimates & Revisions
| Period | EPS Avg | EPS Low | EPS High | EPS Growth | 30d Rev. | Up/Down | Rev. Avg | Rev. Growth | Analysts |
|---|---|---|---|---|---|---|---|---|---|
| Current Q 2026-06-30 |
$-0.00 | $-0.00 | $-0.00 | -103.3% | +98.3% | — | $0.1B | -18.6% | 1 |
| Next Q 2026-09-30 |
$0.01 | $0.01 | $0.01 | 108.9% | +197.7% | — | $0.2B | 52.0% | 1 |
| Current FY 2026-12-31 |
$0.06 | $0.02 | $0.10 | 156.5% | +1628.1% | 0↑ 2↓ | $0.7B | 12.2% | 2 |
| Next FY 2027-12-31 |
$0.18 | $-0.01 | $0.45 | 216.5% | +0.6% | 1↑ 1↓ | $0.8B | 18.6% | 4 |
Current Quarter EPS Revision History
| Timepoint | EPS Estimate | Change |
|---|---|---|
| Current | $-0.001 | |
| 7d ago | $-0.001 | |
| 30d ago | $-0.060 | +0.059 |
| 60d ago | $-0.080 | +0.079 |
| 90d ago | $0.069 | -0.070 |
2 analyst firms have rated this stock: 0 upgrades, 0 downgrades, 1 initiations.
Individual Analyst Actions
| Date | Analyst Firm | Action | Previous Rating | New Rating |
|---|---|---|---|---|
| Mar 24, 2026 | UBS | MAINTAIN | Buy | Buy |
| Mar 24, 2026 | Barclays | MAINTAIN | Underweight | Underweight |
| Dec 9, 2025 | Barclays | INITIATE | — | Underweight |
Monthly Consensus History
| Period | Strong Buy | Buy | Hold | Sell | Strong Sell | Buy % | Distribution |
|---|---|---|---|---|---|---|---|
| Jun 1, 2026 | 3 | 6 | 2 | 1 | 0 | 75% | |
| May 1, 2026 | 3 | 6 | 2 | 1 | 0 | 75% | |
| Apr 1, 2026 | 3 | 6 | 2 | 1 | 0 | 75% | |
| Mar 1, 2026 | 3 | 6 | 2 | 1 | 0 | 75% | |
| Feb 1, 2026 | 3 | 6 | 2 | 1 | 0 | 75% | |
| Jan 1, 2026 | 3 | 6 | 2 | 1 | 0 | 75% |
Strong BuyBuyHoldSellStrong Sell
No congressional trading data available for this ticker. Data is sourced from Senate and House financial disclosure filings.
71°
Bullish
Bearish
Neutral
Bullish
3 mentions
3 bullish
0 bearish
3 time periods
Reddit Sentiment History
| Date | Mentions | Sentiment | Bullish | Bearish | Threads |
|---|---|---|---|---|---|
| May 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
| May 12, 2026 | 1 | 60° Warm | 1 | 0 | 1 |
Recent Reddit Threads
Jun 4, 2026
contract
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
<p>REYKJAVIK, Iceland, June 04, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the devel
Jun 4, 2026
contract
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
<p><b>REYKJAVIK, Iceland, June 4, 2026 </b>- Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and man
Jun 3, 2026
announcement
Main Results of 2026 Annual and Extraordinary General Meeting
<p>The 2026 Annual and Extraordinary General Meeting of Alvotech (the "2026 AGM") was held on June 3, 2026, at Arendt House, 41A Avenue John F. Kenned
Jun 3, 2026
earnings
Main Results of 2026 Annual and Extraordinary General Meeting
<p>REYKJAVÍK, Iceland and LUXEMBOURG, June 03, 2026 (GLOBE NEWSWIRE) -- The 2026 Annual and Extraordinary General Meeting of Alvotech (the "2026 AGM
Jun 2, 2026
other
Alvotech to present at upcoming investor conferences in June
<p><b>REYKJAVIK, </b><b>ICELAND (June 2, 2026) </b>— Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing in
Jun 2, 2026
other
Alvotech to present at upcoming investor conferences in June
<p align="justify">REYKJAVIK, Iceland, June 02, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology c
Jun 1, 2026
other
Alvotech and Islandsbanki renew Market Making Agreement for ALVO Shares Trading on Nasdaq Iceland
<p><b>REYKJAVIK, </b><b>ICELAND (June 1, 2026) </b>— Alvotech (Nasdaq: ALVO) and Islandsbanki have renewed and amended their existing market making ag
May 11, 2026
announcement
Alvotech announces completion of FDA surveillance inspection at Reykjavik facility
<p><b>REYKJAVIK, ICELAND – May 11, 2026</b> – Alvotech (NASDAQ: ALVO; ALVO-SDB), a global biotechnology company specializing in the development and ma
May 11, 2026
earnings
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
<p align="center"><strong><em>- Company remains on track for BLA resubmissions in the second quarter</em></strong><br></p>
May 6, 2026
earnings
Alvotech Q1 2026 Financial Results
<p><b>Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB)</b><br></p>
May 6, 2026
earnings
Alvotech Q1 2026 Financial Results
<p>REYKJAVIK, Iceland, May 06, 2026 (GLOBE NEWSWIRE) -- <br></p> <p><strong>Alvotech (NASDAQ US: ALVO, ICELAND: ALVO, STOCKHOLM: ALVO SDB)</strong><
May 6, 2026
earnings_calendar
ALVO Q1 2026 Earnings Scheduled — 2026-05-06
Apr 30, 2026
other
Alvotech Announces a Change in its Executive Team
<p align="left">REYKJAVIK, Iceland, April 30, 2026 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing
Apr 30, 2026
other
Alvotech Announces a Change in its Executive Team
<p><b>REYKJAVIK, </b><b>ICELAND (April 30, 2026) </b>— Alvotech (NASDAQ: ALVO, the “Company”), a global biotech company specializing in the developmen
Apr 24, 2026
announcement
Alvotech to Report Financial Results for the First Quarter of 2026
<p><b>REYKJAVIK, </b><b>ICELAND (April 24, 2026) </b>— Alvotech (NASDAQ: ALVO; ALVO-SDB) (the “Company”), a global biotechnology company specializing